Utility of positron emission tomography for the detection of disease in residual neck nodes after (chemo)radiotherapy in head and neck cancer

被引:182
作者
Porceddu, SV
Jarmolowski, E
Hicks, RJ
Ware, R
Weih, L
Rischin, D
Corry, J
Peters, LJ
机构
[1] Div Radiat Oncol, Melbourne, Vic, Australia
[2] Peter MacCallum Canc Inst, Div Radiat Oncol, Melbourne, Vic, Australia
[3] Peter MacCallum Canc Inst, Ctr Biostat & Clin Trials, Melbourne, Vic, Australia
[4] Peter MacCallum Canc Inst, Div Haematol & Med Oncol, Melbourne, Vic, Australia
来源
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK | 2005年 / 27卷 / 03期
关键词
PET; head and neck; squamous cell cancer; radiotherapy; chemotherapy;
D O I
10.1002/hed.20130
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
Background. This study evaluates the utility of fluorine-18 fluorodeoxyglucose positron emission tomography (FDG PET) in patients with a node-positive mucosal head and neck squamous cell carcinoma who achieved a complete response at the primary site but had a residual mass in the neck 8 weeks or more after definitive (chemo)radiotherapy. Methods. Between October 1996 and July 2002, 39 eligible patients were identified. The reference PET scan was performed at a median of 12 weeks (range, 8-32 weeks) after treatment. Results. PET showed no metabolic activity in the residual mass in 32 patients. Five of these patients had a neck dissection and were all pathologically negative. The remaining 27 patients were observed for a median of 34 months (range, 16-86 months), with only one locoregional failure. The negative predictive value of PET for viable disease in a residual anatomic abnormality was 97%. Conclusion. Patients who have achieved a complete response at the primary site but have a residual abnormality in the neck that is PET negative approximately 12 weeks after treatment do not require neck dissection and can be safely observed. (C) 2004 Wiley Periodicals, Inc.
引用
收藏
页码:175 / 181
页数:7
相关论文
共 36 条
[1]   Prospective comparison of 18F-FDG PET with conventional imaging modalities (CT, MRI, US) in lymph node staging of head and neck cancer [J].
Adams, S ;
Baum, RP ;
Stuckensen, T ;
Bitter, K ;
Hör, G .
EUROPEAN JOURNAL OF NUCLEAR MEDICINE, 1998, 25 (09) :1255-1260
[2]  
AISNER J, 1994, SEMIN ONCOL, V21, P35
[3]  
Bénard F, 1999, J NUCL MED, V40, P1257
[4]   Radiation with concurrent late chemotherapy intensification ('chemoboost') for locally advanced head and neck cancer [J].
Corry, J ;
Rischin, D ;
Smith, JG ;
D'Costa, IA ;
Hughes, PG ;
Sexton, MA ;
Sizeland, A ;
Lyons, B ;
Peters, LJ .
RADIOTHERAPY AND ONCOLOGY, 2000, 54 (02) :123-127
[5]  
CORRY JF, 2001, CANCER J, V7, P7472
[6]   Complications from planned, posttreatment neck dissections [J].
Davidson, BJ ;
Newkirk, KA ;
Harter, KW ;
Picken, CA ;
Cullen, KJ ;
Sessions, RB .
ARCHIVES OF OTOLARYNGOLOGY-HEAD & NECK SURGERY, 1999, 125 (04) :401-405
[7]   GLUCOSE-UTILIZATION OF CEREBRAL GLIOMAS MEASURED BY [F-18] FLUORODEOXYGLUCOSE AND POSITRON EMISSION TOMOGRAPHY [J].
DICHIRO, G ;
DELAPAZ, RL ;
BROOKS, RA ;
SOKOLOFF, L ;
KORNBLITH, PL ;
SMITH, BH ;
PATRONAS, NJ ;
KUFTA, CV ;
KESSLER, RM ;
JOHNSTON, GS ;
MANNING, RG ;
WOLF, AP .
NEUROLOGY, 1982, 32 (12) :1323-1329
[8]   The usefulness of fluorine 18-labelled deoxyglucose positron emission tomography in the investigation of patients with cervical lymphadenopathy from an unknown primary tumor [J].
Fogarty, GB ;
Peters, LJ ;
Stewart, J ;
Scott, C ;
Rischin, D ;
Hicks, RJ .
HEAD AND NECK-JOURNAL FOR THE SCIENCES AND SPECIALTIES OF THE HEAD AND NECK, 2003, 25 (02) :138-145
[9]  
FORASTIERE AA, 1994, SEMIN ONCOL, V21, P20
[10]   Phase I/II trial of radiation with chemotherapy "boost" for advanced squamous cell carcinomas of the head and neck: Toxicities and responses [J].
Garden, AS ;
Glisson, BS ;
Ang, KK ;
Morrison, WH ;
Lippman, SM ;
Byers, RM ;
Geara, F ;
Clayman, GL ;
Shin, DM ;
Callender, DL ;
Khuri, FR ;
Goepfert, H ;
Hong, WK ;
Peters, LJ .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2390-2395